Therefore, incretin has naturally become the preferred treatment option recommended by major diabetes societies around the world in recent years. How strict is Taiwan's incretin drug health insurance benefits? Why can't sugar friends see it and can't use it? Although the clinical benefits of incretin are obvious, it may be affected by the financial constraints of health insurance and the reduction of health insurance benefits from 2019. Currently, domestic incretin health insurance benefits are limited to glycated hemoglobin of 8.5%, and the duration lasts up to 6 months; or Those who have major cardiovascular diseases such as myocardial infarction and ischemic stroke.
However, because most doctors do not watch old picture restoration the patient's blood sugar remain high, most of them will adjust the drug before the glycated hemoglobin exceeds the standard but does not reach 8.5%, resulting in a huge gap between the health insurance payment threshold and the clinical situation, so that people with diabetes can see But it doesn't work. Glycated hemoglobin conversion average blood sugar level Normal blood sugar control target: fasting blood glucose 130 mg/dL, postprandial blood glucose 160-180 mg/dL, glycosylated hemoglobin below 7% (the control target will vary slightly according to different ages and clinical conditions).
When the glycosylated hemoglobin is 8.5%: the average blood sugar is above 200 mg/dL, which is equivalent to fasting blood sugar close to 200 mg/dL and postprandial blood sugar 250-260 mg/dL, and such values are far from the recommended target. Dr. Li Hongyuan pointed out that those who do not meet the above-mentioned health insurance payment standards must use incretin at their own expense, which will cost an average of 3,000 to 4,000 yuan per month, not including outpatient registration, diagnosis and treatment, care and other related expenses, which accumulate over a long period of time.